Finasteride Tablet, Film Coated
Product Images NDC 50090-6940

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 50090-6940). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

A line graph titled 'Symptom Score in a Long-Term Efficacy and Safety Study' comparing mean change from baseline in symptom scores over four years between Placebo and Finasteride groups. The x-axis shows time points from baseline to Year 4; the y-axis shows mean change from baseline with standard error. Finasteride shows a greater decrease in symptom score over time compared to Placebo.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

A line graph titled 'Percent of Patients Having Surgery for BPH, Including TURP' showing the percentage of patients over 48 months of observation time. Two groups are compared: Finasteride (solid line) and Placebo (dotted line). The graph illustrates lower cumulative surgery rates in the Finasteride group. Below the graph is a table listing cumulative number of events and patients at risk per year for both groups at multiple time points.*

FDA Label Image

Figure3 (Finasteride Fig3)

A line graph comparing the percent of patients developing acute urinary retention over 48 months in Finasteride versus Placebo groups. The y-axis shows percent of patients (0% to 15%), and the x-axis shows observation time in months (0 to 48). Cumulative events and at-risk patient counts are tabulated below for both groups at intervals of 0, 12, 24, 36, and 48 months.*

FDA Label Image

Figure4 (Finasteride Fig4)

Line graph titled "Prostate Volume in a Long-Term Efficacy and Safety Study" showing mean percent change from baseline over 4 years. The graph compares placebo (circle markers) with finasteride (square markers), indicating a decrease in prostate volume with finasteride and an increase with placebo over time. Sample sizes for each group at each time point are listed below the graph.*

FDA Label Image

Figure5 (Finasteride Fig5)

A line graph titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group' showing percent with event on the y-axis and years from randomization on the x-axis. The graph compares four treatment groups: Placebo, Finasteride, Doxazosin, and Combination over approximately 5.5 years, illustrating cumulative incidence trends for each group.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure of finasteride showing the steroidal backbone with multiple rings and attached functional groups including a tert-butyl amide and keto group.*

FDA Label Image

Label Image (Lbl500906940)

Finasteride 5 mg film-coated tablets bottle label from A-S Medication Solutions. The label indicates each tablet contains 5 mg of finasteride. Storage instructions specify keeping the product at 68 to 77 degrees Fahrenheit and protecting it from light. The bottle contains 30 tablets. The label also includes the product NDC 50090-6940 and lot number information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.